Vet Med - Czech, 2011, 56(12):602-611 | DOI: 10.17221/4438-VETMED

TLR agonists activate HPV11 E7-pulsed DCs to promote a specific T cell response in a murine model

X.H. Mao1, X.Z. Chen2, W.W. Zhang1, J.Y. Wang1, L.F. Liu1, Q. Zhou2, K.J. Zhu2, H. Cheng2
1 Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

: Some TLR agonists may up-regulate the activation of dendritic cells caused by viral antigenic peptides and antigen-specific cytotoxic T lymphocytes, which are crucial in HPV vaccine development. We investigated the ability of three TLR agonists, imiquimod, PIC and CpG, to stimulate the maturation of murine BM-DCs loaded with HPV11E7 CTL epitopes, and the subsequent effect on HPV-specific T cell responses and tumour protection in a C57BL/6 mouse model. We found that TLR agonists, mostly PIC and imiquimod, stimulated the maturation of BM-DCs pulsed with HPV11E7 CTL epitope peptide. In combination with the epitope peptide, the TLR agonists CPG and PIC augmented epitope-specific Th1 cytokine production in vivo, while imiquimod and CPG, but not PIC, enhanced Th1 cytokine production in vitro. However, we failed to observe in vivo CTL cytotoxicity and anti-tumour protection upon TLR ligation in our mouse model. Our results demonstrate that TLR agonists activate HPV11E7 CTL epitope pulsed BM-DCs to promote specific Th1 immunity in C57BL/6 mouse model, indicating the promise of TLR agonists as adjuvants for HPV epitope/DC-based multifaceted vaccines against HPV infections such as condyloma accuminatum.

Keywords: HPV - human papillomavirus; TLR - toll-like receptor; DC - dendritic cell

Published: December 31, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mao XH, Chen XZ, Zhang WW, Wang JY, Liu LF, Zhou Q, et al.. TLR agonists activate HPV11 E7-pulsed DCs to promote a specific T cell response in a murine model. Vet Med - Czech. 2011;56(12):602-611. doi: 10.17221/4438-VETMED.
Download citation

References

  1. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, Vries IJ (2008): Dendritic cell vaccination and immune monitoring. Cancer Immunology and Immunotherapy 57, 1559-1568. Go to original source... Go to PubMed...
  2. Blander JM, Medzhitov R (2006): Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808-812. Go to original source... Go to PubMed...
  3. Bowie AG, Haga IR (2005): The role of Toll-like receptors in the host response to viruses. Molecular Immunology 42, 859-867. Go to original source... Go to PubMed...
  4. Chen XZ, Mao XH, Zhu KJ, Jin N, Ye J, Cen JP, Zhou Q, Cheng H (2010): Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Archives of Dermatological Research 302, 57-65. Go to original source... Go to PubMed...
  5. Dearman RJ, Cumberbatch M, Maxwell G, Basketter DA, Kimber I (2009): Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 126, 475-484. Go to original source... Go to PubMed...
  6. Fahey LM, Raff AB, Da Silva DM, Kast WM (2009): Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. Journal of Immunology 182, 2919-2928. Go to original source... Go to PubMed...
  7. Fajardo-Moser M, Berzel S, Moll H (2008): Mechanisms of dendritic cell-based vaccination against infection. International Journal of Medical Microbiology 298, 11-20. Go to original source... Go to PubMed...
  8. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004): Dendritic cell immunotherapy: mapping the way. Nature Medicine 10, 475-480. Go to original source... Go to PubMed...
  9. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, Goldman S, Svensson C, Adami HO, Melbye M (1997): Sexually transmitted infection as a cause of anal cancer. New England Journal of Medicine 337, 1350-1358. Go to original source... Go to PubMed...
  10. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M (2007): TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. Journal of Immunology 178, 3186-3197. Go to original source... Go to PubMed...
  11. Hung CF, Ma B, Monie A, Tsen SW, Wu TC (2008): Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opinion on Biological Therapy 8, 421-439. Go to original source... Go to PubMed...
  12. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM (1992): Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. Journal of Experimental Medicine 176, 1693-1702. Go to original source... Go to PubMed...
  13. Menon C, Polin GM, Prabakaran I, Hsi A, Cheung C, Culver JP, Pingpank JF, Sehgal CS, Yodh AG, Buerk DG, Fraker DL (2003): An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model. Cancer Research 63, 7232-7240.
  14. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M (2011): The combination of TLR-9 adjuvantation and electroporation mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. International Journal of Cancer 128, 473-481. Go to original source... Go to PubMed...
  15. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ (2006): HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncology 100, 469-478. Go to original source... Go to PubMed...
  16. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S, Meijer CJ, Hooijberg E (2005): Preservation and redirection of HPV16E7specific T cell receptors for immunotherapy of cervical cancer. Clinical Immunology 114, 119-129. Go to original source... Go to PubMed...
  17. Sharma S, Dominguez AL, Hoelzinger DB, Lustgarten J (2008): CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunology and Immunotherapy 57, 549-561. Go to original source... Go to PubMed...
  18. Sin JI (2006): Human papillomavirus vaccines for the treatment of cervical cancer. Expert Review of Vaccines 5, 783-792. Go to original source... Go to PubMed...
  19. Stanley M (2008): HPV vaccines: are they the answer? British Medical Bulletin 88, 59-74. Go to original source... Go to PubMed...
  20. Tirapu I, Giquel B, Alexopoulou L, Uematsu S, Flavell R, Akira S, Diebold SS (2009): PolyI:C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation. International Immunology 21, 871-879. Go to original source... Go to PubMed...
  21. van Aubel RA, Keestra AM, Krooshoop DJ, van Eden W, van Putten JP (2007): Ligand-induced differential cross-regulation of Toll-like receptors 2, 4 and 5 in intestinal epithelial cells. Molecular Immunology 44, 3702-3714. Go to original source... Go to PubMed...
  22. Welters MJ, Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007): Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 25, 1379-1389. Go to original source... Go to PubMed...
  23. Xu Y, Zhu KJ, Chen XZ, Zhao KJ, Lu ZM, Cheng H (2008): Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11. Archives of Dermatological Research 300, 235-242. Go to original source... Go to PubMed...
  24. Yoon H, Chung MK, Min SS, Lee HG, Yoo WD, Chung KT, Jung NP, Park SN (1998): Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors. Virus Research 54, 23-29. Go to original source... Go to PubMed...
  25. Zhao KJ, Cheng H, Zhu KJ, Xu Y, Chen ML, Zhang X, Song T, Ye J, Wang Q, Chen DF (2006): Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen. Archives of Dermatological Research 298, 64-72. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.